NuVasive, Inc. (NUVA) President Sells $626,200.00 in Stock

NuVasive, Inc. (NASDAQ:NUVA) President Matthew Link sold 10,100 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $62.00, for a total transaction of $626,200.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.

NuVasive stock traded down $1.82 during midday trading on Friday, hitting $57.96. The company’s stock had a trading volume of 358,406 shares, compared to its average volume of 666,104. The company has a current ratio of 3.75, a quick ratio of 1.96 and a debt-to-equity ratio of 0.80. NuVasive, Inc. has a 12 month low of $43.51 and a 12 month high of $72.41. The stock has a market cap of $3.06 billion, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.19 and a beta of 1.21.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings results on Wednesday, May 1st. The medical device company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.41 by $0.12. NuVasive had a net margin of 4.39% and a return on equity of 15.16%. The firm had revenue of $274.78 million for the quarter, compared to analysts’ expectations of $269.22 million. During the same period in the previous year, the business earned $0.39 earnings per share. NuVasive’s revenue for the quarter was up 5.5% compared to the same quarter last year. On average, equities analysts predict that NuVasive, Inc. will post 2.28 EPS for the current fiscal year.

A number of equities analysts have commented on the stock. BidaskClub raised shares of NuVasive from a “hold” rating to a “buy” rating in a report on Wednesday, May 8th. ValuEngine upgraded NuVasive from a “hold” rating to a “buy” rating in a research note on Tuesday, May 7th. Zacks Investment Research cut NuVasive from a “hold” rating to a “sell” rating in a research note on Monday, February 25th. Cantor Fitzgerald restated a “hold” rating and set a $50.00 price objective on shares of NuVasive in a research note on Monday, February 11th. Finally, Jefferies Financial Group cut shares of NuVasive from a “buy” rating to a “hold” rating and set a $60.00 price objective on the stock. in a research note on Tuesday, February 12th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. NuVasive has an average rating of “Hold” and an average target price of $67.43.

Institutional investors and hedge funds have recently modified their holdings of the stock. Enlightenment Research LLC purchased a new position in NuVasive in the 4th quarter worth about $25,000. Royce & Associates LP purchased a new position in NuVasive in the 4th quarter worth about $25,000. Bessemer Group Inc. purchased a new position in NuVasive in the 4th quarter worth about $50,000. Knott David M purchased a new position in NuVasive in the 1st quarter worth about $114,000. Finally, Rockefeller Capital Management L.P. increased its stake in NuVasive by 251.2% in the 1st quarter. Rockefeller Capital Management L.P. now owns 2,002 shares of the medical device company’s stock worth $114,000 after purchasing an additional 1,432 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This news story was first published by Rockland Register and is the property of of Rockland Register. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://rocklandregister.com/2019/05/31/insider-selling-nuvasive-inc-nuva-president-sells-626200-00-in-stock.html.

About NuVasive

NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Recommended Story: What is diluted earnings per share (Diluted EPS)?

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.